Physician profile
Mohan Kumar
NPI 1710929575
$2,638.39
in general payments reported to CMS, 2019-2025
32 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $179 · 2021: $600 · 2022: $486 · 2023: $531 · 2024: $270 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $246.40 | 2020-2023 | Camzyos, Eliquis |
| Boston Scientific Corporation | $242.03 | 2021-2025 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $215.23 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $187.14 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $182.21 | 2019-2024 | Lifevest |
| Amgen INC. | $180.65 | 2021-2025 | Repatha, Repatha |
| Inspire Medical Systems, INC. | $165.41 | 2023-2025 | Inspire |
| Pfizer INC. | $159.79 | 2019-2023 | |
| Tactile Systems Technology INC | $148.36 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Janssen Pharmaceuticals, INC | $141.82 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.06 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $81.89 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $71.11 | 2024 | Arcalyst |
| Medtronic, INC. | $58.25 | 2021-2025 | Mycarelink |
| Kiniksa Pharmaceuticals, Ltd. | $56.14 | 2022-2023 | Arcalyst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $51.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.98 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $29.25 | 2023 | Inpefa |
| Cvrx, INC. | $29.11 | 2024 | Barostim Neo System |
| Baxter Healthcare | $23.96 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Pulmonx Corporation | $23.69 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $23.54 | 2021 | |
| Impulse Dynamics (USA) INC. | $23.01 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $21.07 | 2024 | Opsumit, Uptravi |
| Avinger INC. | $20.92 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.33 | 2019 | |
| Edwards Lifesciences Corporation | $15.78 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.54 | 2023 | Edarbyclor |
| Abiomed | $14.42 | 2020 | |
| Validus Pharmaceuticals LLC | $14.32 | 2025 | Raldesy |
| Regeneron Healthcare Solutions, INC. | $14.27 | 2019 | |
| Novo Nordisk INC | $14.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.